• Juan Carlos Hernández Boluda, Montse Gómez, and Ariadna Pérez.
• Servicio de Hematología, Hospital Clínico Universitario, Valencia, España. Electronic address: hernandez_jca@gva.es.
• Med Clin (Barc). 2016 Jul 15; 147 (2): 70-5.

AbstractPharmacological inhibition of the kinase activity of JAK proteins can interfere with the signaling of immunomodulatory cytokines and block the constitutive activation of the JAK-STAT pathway that characterizes certain malignancies, including chronic myeloproliferative neoplasms. JAK inhibitors may, therefore, be useful to treat malignancies as well as inflammatory or immune disorders. Currently, the most significant advances have been made in the treatment of myelofibrosis, where these drugs may lead to a remarkable improvement in the control of hyperproliferative manifestations. However, available data suggest that this treatment is not curative of myelofibrosis. In general, JAK2 inhibition induces cytopaenias, with this being considered a class side-effect. By contrast, the extrahaematologic toxicity profile varies significantly among the different JAK inhibitors. At present, there are several clinical trials evaluating the combination of ruxolitinib with other drugs, in order to improve its therapeutic activity as well as reducing haematologic toxicity. Copyright © 2016 Elsevier España, S.L.U. All rights reserved.

27 keywords...

hide…